A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily Compared to Darunavir/Ritonavir (DRV/r) 800 mg/100 mg Once Daily Each Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral naive Adult Subjects.

Trial Profile

A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily Compared to Darunavir/Ritonavir (DRV/r) 800 mg/100 mg Once Daily Each Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral naive Adult Subjects.

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms FLAMINGO
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 May 2017 Status changed from active, no longer recruiting to completed.
    • 22 Jul 2015 Pooled subgroup analysis, results presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top